Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis
Crossref DOI link: https://doi.org/10.1007/s12325-016-0318-5
Published Online: 2016-03-24
Published Print: 2016-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zhou, Zheng-Yi http://orcid.org/0000-0001-9014-8479
Griffith, Jenny
Du, Ella Xiaoyan
Chin, Daniel
Betts, Keith A.
Ganguli, Arijit
Funding for this research was provided by:
AbbVie (US)
Text and Data Mining valid from 2016-03-24